Phaseline

Companies › Aurinia Pharmaceuticals

Aurinia Pharmaceuticals: clinical trials, targets and expected readouts

2 active drug programs in 4 registered trials: 3 Phase 4, 1 Phase 1; Immunology, Neurology; next expected readout Mar 2029.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
voclosporin
Serine/threonine protein phosphatase 2B catalytic subunit, alpha isoform inhibitor
PPP3CAPhase 4Lupus NephritisMar 2029
Aritinercept
BAFF receptor (BAFF-R) agonist
TNFRSF13BPhase 1Myasthenia Gravis, GeneralizedMar 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07225387voclosporinPhase 4Lupus NephritisImmunologyJan 2027
NCT07760480voclosporinPhase 4Lupus NephritisImmunologyApr 2028
NCT07611214voclosporinPhase 4Lupus NephritisImmunologyMar 2029
NCT07596901AritinerceptPhase 1Myasthenia Gravis, GeneralizedNeurologyMar 2029

From the company's SEC filings

Cash of $46m on 2026-09-30; operating cash flow positive

Press releases filed as 8-K in the last year:

Agreements filed with the SEC (item 1.01), last two years

Specialist investors

Held by 3 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

PPP3CA (1) TNFRSF13B (1)

Companies with the same targets

Qilu Pharmaceutical

Companies built like this

TG Therapeutics Vor Biopharma Hope Biosciences Research Foundation Kyverna Therapeutics Q32 Bio

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.